Advertisement

Topics

OncoMed Pharmaceuticals to Report Second Quarter 2015 Financial Results on Monday, August 10, 2015

20:00 EDT 4 Aug 2015 | Globe Newswire

REDWOOD CITY, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics, will announce financial results for the quarter ended June 30, 2015 on Monday, August 10, 2015 after the close of U.S.-based financial markets. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review the results beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).

Analysts and investors can participate in the conference call by dialing (855) 420-0692 for domestic callers and (484) 756-4194 using the conference ID# 5922193.  Please note that slides accompanying management's presentation will be posted to the OncoMed website on the Events page within the Investor Relations section.

The press release and webcast of the conference call will be accessible through a link in the Investor Relations section of the OncoMed website: http://www.oncomed.com. The web broadcast of the conference call will be available for replay through August 25, 2015.

About OncoMed Pharmaceuticals 

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

Contact:
Media & Investors
OncoMed Pharmaceuticals 
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
michelle.corral@oncomed.com
(650) 995-8373
 
Investors
Shari Annes
Annes Associates
shari.annes@oncomed.com
(650) 888-0902

OncoMed Pharmaceuticals, Inc. Logo

NEXT ARTICLE

More From BioPortfolio on "OncoMed Pharmaceuticals to Report Second Quarter 2015 Financial Results on Monday, August 10, 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...